Immunologic Research

, Volume 42, Issue 1, pp 166–181

Genetic engineering of T cells for adoptive immunotherapy

  • Angel Varela-Rohena
  • Carmine Carpenito
  • Elena E. Perez
  • Max Richardson
  • Richard V. Parry
  • Michael Milone
  • John Scholler
  • Xueli Hao
  • Angela Mexas
  • Richard G. Carroll
  • Carl H. June
  • James L. Riley
Article

DOI: 10.1007/s12026-008-8057-6

Cite this article as:
Varela-Rohena, A., Carpenito, C., Perez, E.E. et al. Immunol Res (2008) 42: 166. doi:10.1007/s12026-008-8057-6

Abstract

To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

Keywords

Lentiviral vector CD28 PD-1 TCR Chimeric immunoreceptor Zinc-finger nuclease NOG mice Immunotherapy Adoptive T cell therapy 

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Angel Varela-Rohena
    • 1
  • Carmine Carpenito
    • 1
  • Elena E. Perez
    • 1
  • Max Richardson
    • 1
  • Richard V. Parry
    • 1
  • Michael Milone
    • 1
  • John Scholler
    • 1
  • Xueli Hao
    • 1
  • Angela Mexas
    • 1
  • Richard G. Carroll
    • 1
  • Carl H. June
    • 1
  • James L. Riley
    • 1
  1. 1.Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research InstituteUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations